Other
Neoplasm by Cause
CI-CAN-00000032Explore in graph →
Non-malignant195 active trials4 approved drugs1 evidence items
- NCIt
- C27933
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000032Explore in graph →
Clinical trials
708 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01961063 | Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06375122 | Natural History Study of Kaposi Sarcoma | recruiting | — | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797738 |
| Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma(OPSCC) |
| not yet recruiting |
| N/A |
| 30 |
| Abramson Cancer Center at Penn MedicineOTHER |
| 1 |
| Sep 1, 2026 |
| clinicaltrials |
| NCT05976828 | IBRX-042 In Participants With HPV-Associated Tumors | active not recruiting | Phase 1 | 12 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00867464 | Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls | active not recruiting | — | 8,670 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02659930 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT06628570 | Screening Strategies Among High-risk Populations for Anal Cancer | recruiting | N/A | 500 | Lisa FlowersOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07167225 | Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study) | recruiting | — | 150 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | suspended | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04742387 | Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis | active not recruiting | — | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07308886 | Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05074264 | Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico(CAMPO-101) | active not recruiting | N/A | 1,586 | University of California, San FranciscoOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT06651957 | Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)(ULACNet-104) | active not recruiting | — | 217 | University of California, San FranciscoOTHER | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06754215 | Smoking Cessation Intervention Development for Homeless Youth | terminated | N/A | 179 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04949464 | Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | recruiting | N/A | 100 | AIDS Malignancy ConsortiumNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06145763 | A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial | recruiting | N/A | 776 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06249984 | Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff | recruiting | N/A | 80 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06315881 | Informing Oral Nicotine Pouch Regulations to Promote Public Health | recruiting | Phase 2 | 160 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07439471 | Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance | recruiting | — | 40 | Roswell Park Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07503925 | THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health(THRIVE) | recruiting | Phase 4 | 15 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768787 | Validation of Vaginal Self-Sampling With the Abbott Multi-Collect Swab for HPV Screening in Women Aged 30 to 64 Years(VALMUDES) | completed | — | 1,000 | AMLINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04920344 | Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy | active not recruiting | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05510908 | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC | completed | — | 460 | AIDS Malignancy ConsortiumNETWORK | 2 | Aug 14, 2026 | clinicaltrials |
| NCT06448351 | Manipulating E-Cigarette Nicotine to Promote Public Health | recruiting | N/A | 375 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07418034 | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)(SAVED) | not yet recruiting | Phase 2 | 132 | University of Maryland, BaltimoreOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07425054 | ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer(CHART-AC) | recruiting | Phase 2 | 33 | Jennifer DorthOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06055231 | PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis | not yet recruiting | Phase 1 | 40 | Roswell Park Cancer InstituteOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07493252 | A Behavioral Application for Improving Smoking Cessation Among Smokers | not yet recruiting | N/A | 1,812 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03220022 | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | active not recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05119036 | Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma | completed | N/A | 82 | Indiana UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05797662 | A Study of Propranolol to Treat Kaposi Sarcoma | not yet recruiting | Phase 2 | 25 | AIDS Malignancy ConsortiumNETWORK | 5 | Aug 11, 2026 | clinicaltrials |
| NCT03131934 | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant(ITREC) | completed | Early Phase 1 | 4 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06600568 | Novel Therapeutic Approach for Human T-cell Malignancies | recruiting | — | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04502407 | Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 40 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04900623 | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study | recruiting | Phase 2 | 145 | Jonathan Schoenfeld, MD, MPHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06607874 | Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida | not yet recruiting | — | 100 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT00006436 | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials